NRIX

Over the past six months, Nurix Therapeutics announced new preclinical data at AACR 2026, reported Q1 2026 financial results with a revenue of $6.3 million and a net loss of $87.2 million, and participated in an investor conference. They also presented research at the AACR 2026 Annual Meeting, reported Q4 and Fiscal Year 2025 financial results highlighting the DAYBreak™ program and a $592.9 million cash position, and presented Phase 1 results for bexobrutideg at ASH. Insider selling occurred in May 2026, and analysts are overwhelmingly bullish with 17 buy ratings. The stock has gained 75.0% over the past 12 months.